Cryopreservation of organs by vitrification: perspectives and recent advances

Fahy, Gregory M.; Wowk, Brian; Wu, Jun; Phan, John H.; Rasch, Coen R. N.; Chang, Ah Ram; Zendejas, Eric

doi:10.1016/j.cryobiol.2004.02.002

Cited by 270 publications

(219 citation statements)

References 28 publications

Supporting

Mentioning

210

Contrasting

Unclassified

Order By: Relevance

“…However, cryopreservation of cells encapsulated in the large (≥ ~ 250 µm) microcapsules by slow-freezing has been challenging because the inevitable ice formation always results in significant damage to the microcapsules, which in turn can damage the encapsulated cells (Heng et al 2004;Herrler et al 2006;Stensvaag et al 2004;Wu et al 2007). Although the conventional vitrification approach can overcome this problem, the unusually high concentration CPA needed is detrimental to stress-sensitive cells such as the ES cells (Fahy et al 1987;Fahy et al 1984;Fahy et al 2004b;Rall and Fahy 1985;Wu et al 2007). By careful cryomicroscopy and scanning calorimetry studies, it was identified in a recent publication that water enclosed in ~100 µm (in diameter) alginate microcapsules can be preferentially vitrified over the bulk water (where the microcapsules are suspended) with only 1.4 M DMSO at a cooling rate of 100 o C/min (Zhang et al 2010).…”

Section: Conventional Vitrificationmentioning

confidence: 95%

“…Although a low, non-toxic CPA concentration (usually ≤ ~ 1.5 M) is used in slow-freezing, it is always associated with mechanical and physicochemical injury to cells due to ice formation and slow-freezing (usually ≤ 1 o C/min) induced cell dehydration (Bischof 2000;Gao and Critser 2000;Mazur 1984;Toner 1993). The conventional vitrification approach diminishes ice formation altogether to a harmless level (Fahy et al 1987;Fahy et al 1984;Fahy et al 2004b;Rall and Fahy 1985;Wu et al 2007). The unusually high (as high as 7 M) concentration of CPA required, however, can result in significant metabolic and osmotic injury to cells (Chen et al 2000;Chen et al 2001a;Fahy et al 2004a;Fowler and Toner 2005;Heng et al 2005;Hunt et al 2006).…”

Section: Preservation Of Embryonic Stem (Es) Cellsmentioning

confidence: 99%

“…1) has also been studied for cryopreservation of both cells and tissue. In this approach, biological samples (state A) are first loaded with a very high concentration of CPAs (up to ~ 7 M, state F) (Fahy et al 1984;Fahy et al 2004b;Rall and Fahy 1985). The samples are then cooled directly from ambient temperature to a cryogenic temperature usually in liquid nitrogen (state II) and stored there for future use.…”

Section: Conventional Vitrificationmentioning

confidence: 99%

“…In other words, no (or negligible) ice formation or freezing will occur in the sample during cooling (Fahy et al 1984;Fahy et al 2004b;Rall and Fahy 1985). Conventional vitrification (A→F→II in Fig.…”

Section: Conventional Vitrificationmentioning

confidence: 99%

See 3 more Smart Citations

Preservation of Embryonic Stem Cells

He¹

2011

Methodological Advances in the Culture, Manipulation and Utilization of Embryonic Stem Cells for Basic and Practical Applicatio

View full text Add to dashboard Cite

Section: Conventional Vitrificationmentioning

confidence: 95%

Section: Preservation Of Embryonic Stem (Es) Cellsmentioning

confidence: 99%

Section: Conventional Vitrificationmentioning

confidence: 99%

Section: Conventional Vitrificationmentioning

confidence: 99%

See 2 more Smart Citations

Preservation of Embryonic Stem Cells

He¹

2011

Methodological Advances in the Culture, Manipulation and Utilization of Embryonic Stem Cells for Basic and Practical Applicatio

View full text Add to dashboard Cite

“…Synthetic polymers such as polyvinylpyrrolidone (PVP), a polyvinyl alcohol and vinyl acetate copolymer (Super cool X-1000), and a polyglycerol (Super cool Z-1000) were used to bind nucleators, and prevent ice formation and de-vitrification in an ethylene glycol-based cryoprotectant solution [4,5]. These synthetic polymers were chosen over others because they have been shown to decrease crystallization, and improve functionality of tissues warmed and recovered after vitrification when compared to solutions without these polymers, and did not increase tissue toxicity [6,7].…”

Section: Choosing the Vitrification Protocolmentioning

confidence: 99%

Good manufacturing practice requirements for the production of tissue vitrification and warming and recovery kits for clinical research

Laronda

McKinnon

Ting

et al. 2016

J Assist Reprod Genet

View full text Add to dashboard Cite

Products that are manufactured for use in a clinical trial, with the intent of gaining US Food and Drug Administration (FDA) approval for clinical use, must be produced under an FDA approved investigational new drug (IND) application. We describe work done toward generating reliable methodology and materials for preserving ovarian cortical tissue through a vitrification kit and reviving this tissue through a warming and recovery kit. We have described the critical steps, procedures, and environments for manufacturing products with the intent of submitting an IND. The main objective was to establish an easy-to-use kit that would ensure standardized procedures for quality tissue preservation and recovery across the 117 Oncofertility Consortium sites around the globe. These kits were developed by breaking down the components and steps of a research protocol and recombining them in a way that considers component stability and use in a clinical setting. The kits were manufactured utilizing current good manufacturing practice (cGMP) requirements and environment, along with current good laboratory practices (cGLP) techniques. Components of the kit were tested for sterility and endotoxicity, and morphological endpoint release criteria were established. We worked with the intended down-stream users of these kits for development of the kit instructions. Our intention is to test these initial kits, developed and manufactured here, for submission of an IND and to begin clinical testing for preserving the ovarian tissue that may be used for future restoration of fertility and/or hormone function in women who have gonadal dysgenesis from gonadotoxic treatment regimens or disease.Keywords Good manufacturing practice . Vitrification . Ovary . Oncofertility Purpose Current Good Manufacturing Practice (cGMP) regulations are enforced by the US Food and Drug Administration in order to ensure the quality of manufactured drug products. These guidelines are listed in the 21 Code of Federal Regulations (CFR) part 211 [1]. cGMPs include a set of guidelines for facility standards, proper documentation, and implementation of procedures. Additionally, equipment within facilities used for drug manufacturing must be monitored and calibrated under cGMP guidelines and personnel must be properly trained and proficient in the facility procedures in order to be compliant. Current good laboratory practices (cGLPs) are additional guidelines that ensure that the data generated by testing the Capsule The main objective of this study was to establish an easy-to-use kit for standardized ovarian tissue vitrification and recovery. We have described the critical steps, procedures, and environments for manufacturing media kits intended for an Investigational New Drug (IND) application for future clinical trials.Electronic supplementary material The online version of this article

show abstract

Cryopreservation of Plant Cells

Keller¹,

Senula²,

Höfer³

et al. 2013

Encyclopedia of Industrial Biotechnology

View full text Add to dashboard Cite

Cryopreservation, storage of living tissues in or above liquid nitrogen, is increasingly used to preserve germplasm in the long term. When cooling plant tissue to low temperatures, water may destroy cells by osmotic drying or disruption of organelles by forming ice crystals. The organisms accumulate cryoprotective substances to adapt to freezing. Cryoprotectants trigger glass transition (vitrification), when temperature is cooled down rapidly. In the course of cryopreservation, tissues are imposed by various influences causing oxidative stress: wounding, dehydration, and direct liquid nitrogen effect. Occurring reactive oxygen species may be measured and antioxidant substances may be added. Cell structure alterations, water status, regeneration from cryopreservation injury, and genetic and epigenetic changes, which may occur, were investigated. Various plant tissues were cryopreserved: dedifferentiated cells and tissues; shoot tips; axillary buds and other meristematic plant parts; dormant buds of woods species, seeds, embryos, and embryo axes; and pollen. Several main methods were used: slow freezing, vitrification, and encapsulation. Liquid nitrogen can also be used to eliminate viruses from the organs (cryotherapy). The existence of endogenous or contaminating microorganisms needs special attention. Furthermore, technological considerations and the use of cryopreservation to maintain transgenic or patented material need to be mentioned.

show abstract

Cryopreservation of organs by vitrification: perspectives and recent advances

Cited by 270 publications

References 28 publications

Preservation of Embryonic Stem Cells

Preservation of Embryonic Stem Cells

Good manufacturing practice requirements for the production of tissue vitrification and warming and recovery kits for clinical research

Cryopreservation of Plant Cells

Contact Info

Product

Resources

About